TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
oleh: Caleb Gonzalez, Sarah Williamson, Seth T. Gammon, Sarah Glazer, Joon Haeng Rhee, David Piwnica-Worms
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2023-01-01 |
Deskripsi
TLR5 agonists in combination with immune checkpoint therapies (ICT) enhance survival in ICT-refractory murine 4T1 mammary carcinoma and B16-F10 melanoma tumors. Low serum levels of G-CSF and CXCL5 correlate with enhanced survival.